Referenties Evrysdi® 1. Bijsluiter Evrysdi (risdiplam). Geraadpleegd op 7 maart 2022. Beschikbaar via https://www.roche.nl/content/dam/rochexx/roche-nl/ pdf/Evrysdi_II03_18nov2021_Leaf.pdf 2. SmPC Evrysdi (risdiplam). Geraadpleegd op 7 maart 2022. Beschikbaar via https://www.roche.nl/content/dam/rochexx/roche-nl/ pdf/Evrysdi_II03_18nov2021_SmPC.pdf Referenties Idefirix 1. Amro A, et al. J Ren Care 2014;40:23-33. 2. Zazzeroni L, et al. Kidney Blood Press Res 2017;42:717-727. 3. Sinnakirouchenan R, et al. Adv Chronic Kidney Dis 2011;18:428-432. 4. Jordan SC, et al. N Engl J Med. 2017;377(5):442-453. 5. Lonze BE, et al. Ann Surg. 2018;268(3):488–496. 8. 6. ManookM, et al. Lancet. 2017;389(10070):727–734 7. Jordan SC, et al. Immunotherapy 2015;7:377-398. 8. Aubert O,et al. BMJ 2015;351:h3557. 9. SmPC Idefirix oktober 2021 10. Jordan SC, et al. Transplantation 2021;105:1808-1817. 11. Kjellman C, et al. Am J Transplant 2021;21:3907-3918. 12. Winstedt L, et al. PLoS One. 2015;10(7):e0132011. Referenties Natpar 1. Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011 Oct;26(10):2317-37. 2. SmPCNatpar 3. Astor MC, Lovas K, Debowska A et al. Epidemiology and HealthRelated Quality of Life in Hypoparathyroidism in Norway. J Clin Endocrinol Metab. 2016;101(8):3045-53. 4. David K, Moyson C, Vanderschueren D, Decallonne B. Long-term complications in patients with chronic hypoparathyroidism: a crosssectional study. Eur J Endocrinol. 2018. 5. Almquist M, Ivarsson K, NordenstromE, Bergenfelz A. Mortality in patients with permanent hypoparathyroidism after total thyroidectomy. Br J Surg. 2018;105(10):1313-8. 6. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J BoneMiner Res. 2013;28(11):2277–2285. 7. Gesek FA, Friedman PA. On the mechanism of parathyroid hormone stimulation of calcium uptake by mouse distal onvoluted tubule cells. J Clin Invest. 1992;90(3):749–758. 8. Mitchell DM, Regan S, CooleyMR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97(12):4507–4514. 9. Kurokawa K. Calcium-regulating hormones and the kidney. Kidney Int. 1987;32(5):760–771. 10. Chen KS, Gosmanova EO, Curhan GC, et al, Five-year Estimated Glomerular Filtration Rate in PatientsWith Hypoparathyroidism TreatedWith andWithout rhPTH(1–84). J Clin Endocrinol Metab, October 2020, 105(10):1–9 11. Vokes T. Quality of life in hypoparathyroidism. Bone. 2019 Mar;120:542-547. References Pemizyre 1. Bañales JM, et al. Nat Rev Gastroenterol Hepatol. 2020:17:557–88 2. Rizvi S, et al. Nat Rev Clin Oncol. 2018;15:95–111 3. Blechacz B. Gut Liver. 2017;11:13–26 4. Bibeau K, et al. J Clin Oncol. 2021;39(Suppl 3):Abstract 277 5. Valle JW, et al. Cancer Discov. 2017;7:943–62 6. Bekaii-Saab TS, et al. Ann Oncol. 2021;32:1111–26 7. Lamarca A, et al. Ann Oncol. 2014;25:2328–38 8. Lamarca A, et al. Lancet Oncol. 2021;22:690–701 9. BoradMJ, et al. Curr Opin Gastroenterol. 2015;31:264–8 10. Silverman IM, et al. Cancer Discov. 2021;11:326–39 11. 11.Ross JS, et al. Oncologist. 2014;19:235–42 12. Farshidfar F, et al. Cell Rep. 2017:18:2780–94 13. GrahamRP, et al. HumPathol. 2014;45:1630–8 14. Jain A, et al. JCOPrecis Oncol. 2018:2;1–12 15. PEMAZYRE® (pemigatinib). Summary of Product Characteristics, February 2022 16. Liu PCC, et al. PLoS ONE. 2020;15(4):e0231877 17. Abou-Alfa GK, et al. Lancet Oncol. 2020;21:671–84 18. Abou-Alfa GK, et al. Presented at ASCO 2021; Poster 4086 19. Abou-Alfa GK, et al. Presented at ESMOGI 2021; Oral SO-4 20. Ghassan K. Abou-Alfa, Journal of Clinical Oncology 2021 39:15_suppl, 4086-4086 21. https://pharma-trend.com/pharma-award/#Gewinner_der_Awards_ Das_innovativste_Produkt_2021 Referenties Poteligeo 1. POTELIGEO productinformatie https://www.ema.europa.eu/en/ documents/product-information/mogamulizumab-epar-product information_en.pdf 2. Mogamulizumab – EPAR - Public assessment report https://www. ema.europa.eu/documents/assessment-report/mogamulizumabepar-public-assessment-report_en.pdf 3. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas; Version 1.2022 4. Willemze R, Cerroni L, Kempf W, et al. Blood. 2019;133(16):17031714. 5. Trautinger F, Eder J, Assaf C, et al. Eur J Cancer. 2017;77:57-74. 6. Lebas E, Collins P, Somja J, et al. Dermatol Ther. 2021;11(6):19311951. 7. Willemze R et al., Ann Oncol. 2018;29(4):1-29 8. DemierreMF, Gan S, Jones J, Miller DR. 2006;107(10):2504-2511. 9. Ottevanger R, van Beugen S, Evers AWM, et al. J Eur Acad Dermatol Venereol. 202;35(12):2377-2387. 10. Scarisbrick JJ, Quaglino P, Prince HM, et al. The PROCLIPI Br J Dermatol. 2019;181(2):350-357. 11. KimYH, Bagot M, Pinter-Brown L, et al. Lancet Oncol. 2018;19(9):1192-1204. 12. Porcu P, Hudgens S, Horwitz S, et al.. Clin LymphomaMyeloma Leuk. 2021;21(2):97-105. Referenties Vocabria + Rekambys 1 DHHS Guidelines – Beschikbaar op www.clinicalinfo.hiv.gov/en/ guidelines. Bezocht Feb 2022 2 EuropeanMedication Association. Summary of Product Characteristics (SMPC): Vocabria. 3 EuropeanMedication Association. Summary of Product Characteristics (SMPC): Rekambys. 4 Trezza C, Ford SL, SpreenW, Pan R, Piscitelli S. Formulation and pharmacology of long-acting cabotegravir. Current opinion in HIV and AIDS. 2015;10(4):239-45. 5 Müller RH, Gohla S, Keck CM. State of the art of nanocrystals-- special features, production, nanotoxicology aspects and intracellular delivery. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2011;78(1):1-9. 6 Orkin C, Arasteh K, Gorgolas Hernandez-MoraM, Pokrovsky V, Overton ET, Girard PM, et al. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for hiv-1 Infection. N Engl J Med. 2020;382(12):1124-35. 7 Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, MasiaM, et al. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N Engl J Med. 2020;382(12):1112-23. 8 Overton ET, Richmond GJ, Rizzardini G, Jaeger H, Orrell C, Nagimova F. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with hiv-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet (London, England). 2020. Referenties Takzhyro 1. LumryWR. Overview of epidemiology, pathophysiology, and disease progression in hereditary angioedema. American journal of managed care, The. 2013;19(7 Suppl):s103-110. 2. Jolles S, Williams P, Carne E, et al. A UK national audit of hereditary and acquired angioedema. Clin Exp Immunol. 2014;175(1):59-67. 3. Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol. 2006;101(3):619-627. 4. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267-274. 5. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036. 6. LumryWR. Overview of epidemiology, pathophysiology, and disease progression in hereditary angioedema. Am J Manag Care. 2013;19(7 Suppl):s103-110. 7. Bowen T, Cicardi M, Bork K, et al. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, andManagement of Hereditary Angioedema. Ann Allergy Asthma Immunol. 2008;100(1 Suppl 2):S30-40. 8. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3 Suppl):S51-131. 9. CugnoM, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. International Immunopharmacology. 2003;3(3):311-317. 34 | PRIX GALIEN NEDERLAND 2022
RkJQdWJsaXNoZXIy ODY1MjQ=